louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01619449: Continuous Renal Replacement Therapy in the Setting of Orthotopic Liver Transplant
Official title: Continuous Renal Replacement Therapy in the Setting of Orthotopic Liver Transplant: A Randomized Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Acute Kidney Injury
Liver Disease
Chronic Kidney Disease
End Stage Kidney Disease
Keywords: Acute Kidney Injury
Continuous Renal Replacement Therapy
Liver Transplant
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2012-06-14
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy of continuous renal replacement therapy (CRRT) during orthotopic liver transplantation (OLT) in clearing excess solutes and improving acid-base parameters. The investigators hypothesize that the use of intra-operative CRRT in OLT recipients is associated with increased solute removal and improved acid-base statues when compared to controls who do not receive CRRT

Detailed description: as above

Eligibility criteria: Inclusion Criteria:

* Age 18 or older and able to sign consent (or surrogate)
* Receiving liver or combined liver-kidney transplant
* eGFR \< or equal to 40 ml/min immediately prior to transplant or currently on any form of renal replacement therapy for acute kidney injury or end-stage renal disease
* Pre-operative potassium of \< or equal to 5.5 mEq/L

Exclusion Criteria:

* Pre-operative hemoglobin \< or equal to 7 g/dL
* Pre-operative weight \> or equal to 125 kig

Primary outcomes:
measure: Solute Clearance
timeFrame: Intra-operative time
Secondary outcomes:
measure: Renal function and patient outcomes
timeFrame: 1 year post-operatively
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago Medicine
state: Illinois
Study officials:
affiliation: University of Chicago
name: Jay L Koyner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01243736: Assessment of Combined Bowel Preparation for Capsule Endoscopy Study
Official title: Assessment of Combined Bowel Preparation for Capsule Endoscopy Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Gastrointestinal Hemorrhage
Keywords: anemic
bleeding
blood in stool
abdomen pain
Gastrointestinal bleeding
capsule endoscopy (CE)
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2010-11-18
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The investigators are conducting a study to see if taking a bowel preparation before having a capsule endoscopy is more helpful than the standard preparation of not eating after 7 PM the night before a capsule endoscopy in making it easier to see the small bowel in order to find the source of gastrointestinal bleeding.

Detailed description: This is a single-blind, prospective randomized controlled study to determine if a combination of purgative agent, prokinetic agent, simethicone, and position will improve small bowel visualization, diagnostic yield, and completion rate of capsule endoscopy.

Eligibility criteria: Inclusion Criteria:

1. Age \> 18 years old
2. Gastrointestinal bleeding as indication for capsule endoscopy.
3. Ability to give informed consent

Exclusion Criteria:

1. Subject has an allergy to polyethylene glycol or other adverse reaction to a previous bowel preparation with PEG3350 (MoviPrep®), metoclopramide, or simethicone;
2. Subjects has gastrointestinal motility disorder;
3. Subjects had stomach or small bowel resection;
4. Pregnancy;
5. Subjects has pheochromocytoma;
6. Subjects has uncontrolled hypertension;
7. Subjects has seizure disorders;
8. Subjects has concurrent MAO inhibitor use;
9. Subject has G6PD deficiency;
10. Subjects has swallowing disorder (including impaired gag reflex);
11. Subjects has hyponatremia with serum sodium less than 130 mm0l/L

Primary outcomes:
measure: Improvement small bowel visualization, diagnostic yield, and complete rate of capsule endoscopy
timeFrame: 1 year
Secondary outcomes:
measure: Safety outcomes and Patient satisfaction
timeFrame: 1 year
measure: gastric transit time
timeFrame: 1 year
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Stephanie L. Hansel, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Mayo Clinic
name: Elizabeth Rajan, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hansel SL, Murray JA, Alexander JA, Bruining DH, Larson MV, Mangan TF, Dierkhising RA, Almazar AE, Rajan E. Evaluating a combined bowel preparation for small-bowel capsule endoscopy: a prospective randomized-controlled study. Gastroenterol Rep (Oxf). 2019 Oct 19;8(1):31-35. doi: 10.1093/gastro/goz054. eCollection 2020 Feb.
Clinical trial NCT04597749: Nebula Study - Screener Apps and HSAT vs. PSG Comparison
Official title: Nebula Study: Comparison of Sleep Screener Apps and Home Sleep Apnea Tests to Polysomnography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep Apnea, Obstructive
Keywords: OSA
Sleep Apnea
OSA Screeners
Home Sleep Apnea Test
Lead sponsor: ResMed
Sponsor class: INDUSTRY
First posted: 2020-10-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: This is a prospective, unblinded, open-label, single group study. All subjects will undergo concurrent screener app, HSAT testing, and in-lab polysomnography.


Eligibility criteria: Inclusion Criteria:

* Participant is 18 years of age or older
* Participant is willing to provide informed consent
* Participant is willing to participate in all study related procedures

Exclusion Criteria:

* Unable to cease PAP therapy during PSG (if currently using)
* Requires use of oxygen therapy during sleep
* Diagnosis of untreated clinically relevant sleep disorder (other than SDB)
* Pregnant
* Participant is unsuitable to participate in the study in the opinion of the investigator
* Participant has a permanent pacemaker, sustained non-sinus cardiac arrhythmias, and/or takes alpha blocker or short acting nitrate medication.

Primary outcomes:
measure: AHI value. Clinical decision for treatment output (Y to CPAP or N to CPAP) of Screener apps and HSAT compared to PSG.
timeFrame: Day 1
Secondary outcomes:
measure: OSA severity categories (normal, mild, moderate, severe) of Screnner apps and HSAT compared to PSG.
timeFrame: Day 1
Other outcomes:
Locations:
city: Maplewood
country: United States
facility: Clayton Sleep Institute
state: Missouri
Study officials:
References:
Clinical trial NCT04894149: Prehabilitation and Rehabilitation for Patients With Oesophageal Cancer
Official title: Prehabilitation and Rehabilitation for Patients With Oesophageal Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Esophageal Cancer
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
First posted: 2021-05-20
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Patients with oesophageal cancer selected for oncological and surgical treatment with curative intent are offered supervised physiotherapy and home-based training before and after surgery.

Detailed description: Patients with loco-regional oesophageal cancer who will receive neoadjuvant chemotherapy or chemoradiotherapy followed by surgery and sometimes adjuvant chemotherapy are eligible to be enrolled in the trial. Study treatment is supervised group training twice weekly and home-based training three times weekly during neoadjuvant treatment and after surgery.

Eligibility criteria: Inclusion Criteria:

* Histopathologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma in the oesophagus or cardia (Siewert I or II), cT1 N+ or cT2-4a any N, M0, according to the 8th version of the AJCC TNM classification.
* Assessed at a multidisciplinary conference to be suitable for curatively intended oncological and surgical treatment.
* Age \> 18 years.
* Performance status ECOG 0-2.
* Patient has provided written informed consent.

Exclusion Criteria:

* Previous radiotherapy in the thorax (except for tangential field radiotherapy for breast cancer).
* Inability to understand written and spoken instructions and to comply with protocol requirements.

Primary outcomes:
measure: Adherence to exercise sessions.
timeFrame: Up to 40 weeks
measure: Un-planned interruptions in the prehabilitation/rehabilitation programme
timeFrame: Up to 40 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Karolinska University hospital
Study officials:
References:
Clinical trial NCT05437549: Evaluating PVI Using CMR
Official title: CMR Characterization of Ablation Lesions Following Pulmonary Vein Isolation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Atrial Fibrillation
Lead sponsor: Amsterdam UMC, location VUmc
Sponsor class: OTHER
First posted: 2022-06-29
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Using state of the art cardiac magnetic resonance imaging techniques, characterization of ablation lesions in the early phase after pulmonary vein isolation ablation in atrial fibrillation patients, and relate findings to the ablation scar at 3 months follow up and atrial fibrillation-free survival at 1 year.


Eligibility criteria: Inclusion Criteria:

* Adult patients (age ≥18 years old)
* Paroxysmal or persistent AF meeting guideline criteria.
* Anticipated PVI using index-guided radiofrequency ablation techniques.
* Availability of LGE-CMR images within 3 months before anticipated PVI.

Exclusion Criteria:

* History of catheter ablation
* History of cardiac surgery.
* History of chest radiation therapy
* Estimated glomerular filtration rate (eGFR) \<45 ml/min/kg
* Known (or suspected) allergic reaction to gadolinium
* Contraindications for CMR (such as claustrophobia, certain implants, devices, high body mass index).
* Inability to schedule CMR \<48h after PVI
* Long-term use of anti-inflammatory medication, except for the use of nonsteroidal anti-inflammatory drugs
* Autoimmune disease or chronic inflammatory illness.
* Pregnancy of breast feeding

Primary outcomes:
measure: Ablaton scar
timeFrame: 3 months
Secondary outcomes:
measure: AF recurrence
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06997549: Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
Official title: Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Depression
OCD
Anxiety Depression
Lead sponsor: Neuronetics
Sponsor class: OTHER
First posted: 2025-05-30
Enrollment: 12000
Sex: ALL
Minimum age (years): 5
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Individuals who received mental health treatment at a Greenbrook Center and the data is available in their database.

Brief summary: The study involves multiple retrospective analyses to understand the utilization of mental health treatments provided at Greenbrook and their effectiveness

Detailed description: this is a retrospective data analysis study that will utilize the already collected data as clinical care and will help understand the utilization and efficacy of various treatment options available for various mental heath conditions.

Eligibility criteria: Inclusion Criteria:

* Male or female reported in database and not an invalid entry
* Age reported and not an invalid entry
* Treatment date in 2011 or later.

Exclusion Criteria:

• Incomplete information on treatment parameters

Primary outcomes:
measure: change in clinical outcome scores from baseline to post treatment
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Malvern
country: United States
facility: Neuronetics
state: Pennsylvania
Study officials:
affiliation: Neuronetics
name: Eleanor Cole, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01503749: Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver Cirrhosis
Official title: The Role of Peripheral Mononuclear Cells for Treatment of Advanced Liver Cirrhosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Liver Cirrhosis
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2012-01-04
Enrollment: 9
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The investigators aim to investigate the safety and efficacy of peripheral blood monocyte for the treatment of patients with advanced liver cirrhosis.

Detailed description: G-colony stimulating factor(5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis. On the day 4th, plasmapheresis will be done to collect peripheral blood mononucleated cells

. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.

Eligibility criteria: Inclusion Criteria:

1. 20 =\< Age \< 80
2. Advanced liver cirrhosis with Child-Pugh score 8 or 9 (including patients who have no radiologic evidence of remnant HCC for more than 2 years after treatment)

Exclusion Criteria:

1. HBsAg-positive
2. Active status of hepatocellular carcinoma (HCC) (except patients who have no radiologic evidence of remnant HCC for more than 2 years after treatment)
3. History of hemochromatosis and/or autoimmune hepatitis
4. Pregnant women or lactating women
5. Hemoglobin \< 8g/dL (male), 7.5g/dL (female) or white blood cell (WBC) \<1,500 mm3 or Neutrophils \<500/mm3 or platelet count \<50,000/mm3
6. Serum creatinine\> 1.5 x normal upper limit or creatinine clearance \<60 ml/min
7. Presence of signs of malignant tumors or tumor suspected symptoms, or history of malignant tumors with recurrence rate greater than 20% within two years
8. Gastrointestinal bleeding within the last 3 months or if there is a history of spontaneous bacterial peritonitis
9. Presence of portal vein thrombosis
10. Presence of acute infections

Primary outcomes:
measure: Number of Participants With Severe Adverse Events
timeFrame: up to 6 months
Secondary outcomes:
measure: Mean Change in Child-Pugh Score and Model For End-Stage Liver Disease (MELD) Score
timeFrame: Baseline and Week 24
Other outcomes:
Locations:
Study officials:
affiliation: Seoul National University Hospital
name: Jung-Hwan Yoon, M.D., Ph. D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03690349: Mold Sensitization Associated Severe Asthma Exacerbation
Official title: Is Mold Sensitization Associated With Severe Asthma Exacerbation in Children?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Keywords: severe asthma exacerbation
Mold sensitization
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2018-10-01
Enrollment: 102
Sex: ALL
Minimum age (years): 1
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Asthmatic children aged 1-15 years old from Pediatric Allergy and Immunology division devided in to 2 groups: 1. hospitalized due to severe asthma exacerbation in a preceding year and 2. without severe asthma exacerbation in a preceding year

Brief summary: Mold sensitization is associated with severe asthma exacerbation.

Detailed description: Mold sensitization has been reported to be one of the factors that is associated with severe asthma exacerbation (SAE). The objective is to identify the factors that are associated with SAE in asthmatic children particularly mold sensitization.

Eligibility criteria: Inclusion Criteria:

* Asthmatic children aged 1-15 years old from Pediatric Allergy and Immunology division with hospitalized due to severe asthma exacerbation in a preceding year and without severe asthma exacerbation in a preceding year

Exclusion Criteria:

* Other serious systemic diseases, pregnant, lactation

Primary outcomes:
measure: Association between mold sensitization and severe asthma exacerbation
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06428149: Three Types of Papilla Incision in Periodontal Surgery
Official title: Wound Healing After Different Types of Papilla Incision in Periodontal Reconstruction Surgery. a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Periodontitis
Periodontal Diseases
Periodontal Pocket
Lead sponsor: Universidad de Murcia
Sponsor class: OTHER
First posted: 2024-05-24
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Three types of papilla incision in periodontal reconstruction techniques will be compared.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with periodontal disease.
* Active residual pockets associated with intraosseous defects that did not resolve with non-surgical treatment after 1 year of maintenance.
* Intraosseous lesions with probing depth greater than 5 mm or extension of the radiographic defect greater than 4 mm.
* Plaque index and bleeding index less than 30%.

Exclusion Criteria:

* Systemic disease that contraindicates periodontal surgery.
* Pregnant women.
* Third molars or teeth with incorrect endodontic or restorative treatment.

Primary outcomes:
measure: Bleeding on probing
timeFrame: 12 months
measure: Clinical attachment level (CAL)
timeFrame: 12 months
measure: Probing pocket depth (PD)
timeFrame: 12 months
measure: Recession (REC)
timeFrame: 12 months
measure: Location of the tip of the papillae (TP)
timeFrame: 12 months
measure: Keratinized tissue width (KT)
timeFrame: 12 months
Secondary outcomes:
measure: Supra-alveolar attachment gain (SUPRA-AG)
timeFrame: 12 months
Other outcomes:
Locations:
city: Murcia
country: Spain
facility: Centro Odontologico Del Sureste Slp
Study officials:
References:
Clinical trial NCT02608749: Osteoporosis and Fall Prevention High Risk Population Intervention and Follow up in the Metropolitan Area
Official title: Osteoporosis and Fall Prevention High Risk Population Intervention and Follow up in the Metropolitan Area
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoporosis
Fracture
Keywords: Osteoporosis
Fall
Fracture
Sacopenia
Body Composition
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2015-11-20
Enrollment: 151
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: BACKGROUND: The deterioration of musculoskeletal system imposes significant impact on physical activity in older adults.

METHODS: This was a randomized, parallel-group, prospective study. All participants received education program including home-based exercise. The IC group consisted of different modalities of exercise while the LEE group performed machine-based exercise. Body composition, muscle strength, and physical performance were measured at their baseline and 3 months follow-up.


Eligibility criteria: Inclusion Criteria:

1. older than 50 years of age
2. high risk as defined from one of the following criteria

   * score\>=1 on one minute osteoporosis risk questionnaire
   * 10 year predicted fracture risk \>=20% for major osteoporosis fracture or \>=3% for hip fracture from FRAX
   * fall\>=2 times in pass 1 year
3. having a bone mineral density test within one year period
4. having the capability to understand the study and complete the study interventions
5. willing to participate for the intervention and study follow ups

Exclusion Criteria:

1. If patients were unable to meet at least the above inclusion criteria.

Primary outcomes:
measure: Lower extremity extensor power measured by isokinetic resistance equipment
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Ding-Cheng Chan
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00727649: Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence
Official title: Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Fecal Incontinence
Keywords: fecal incontinence
adults
diarrhea
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2008-08-04
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate and compare treatment with fiber and loperamide for fecal incontinence.

Detailed description: Fecal incontinence (FI) affects 4-24% adults in the community and greatly impacts quality of life. Both fiber and loperamide are common, first-line treatments for diarrhea-associated FI in primary care. No known studies exist that compare fiber and loperamide for diarrhea-predominant FI. Further knowledge is needed to define which treatment is more effective and to compare drug tolerability (side effects) for FI. This study will also look at changes in quality of life with treatment and potential mechanisms of drug treatment.

Eligibility criteria: Inclusion Criteria:

* weekly fecal incontinence

Exclusion Criteria:

* fecal impaction
* inability to complete a baseline 1-week bowel diary
* rectal prolapse
* any prior radiation to the pelvis
* colo-rectal cancer
* rectal fistula
* inflammatory bowel disease
* neurological diseases (spinal cord injury, multiple sclerosis, Parkinson's disease)
* constipation (\<2 bowel movements/week) or total colectomy

Primary outcomes:
measure: 7-day Bowel Diary, Number of Fecal Incontinence Episodes
timeFrame: 6 weeks and 12 weeks
measure: Percentage of Bowel Movements With Incontinence
timeFrame: 4 weeks
Secondary outcomes:
measure: Fecal Incontinence Severity Index Score, FISI
timeFrame: baseline, 4 week and 12 weeks
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: VA Medical Center, Birmingham
state: Alabama
Study officials:
affiliation: VA Medical Center, Birmingham
name: Alayne D Markland, DO MSc
role: PRINCIPAL_INVESTIGATOR
References: